Fulvestrant

Fulvestrant 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Solid Tumor、HR+/HER2- Breast Cancer、HR+, HER2-, Advanced Breast Cancer、CCNE1 Amplification。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Fulvestrant 研究

• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  III 期招募中美国Argentina澳大利亚比利时NCT07062965

• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  I 期 / II 期招募中美国加拿大Czechia丹麦NCT07288359

• SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

  I 期 / II 期招募中美国NCT04923542

• Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

  III 期招募中中国NCT06998108

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  III 期招募中美国Argentina澳大利亚奥地利NCT06982521

• Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  III 期招募中美国Argentina澳大利亚比利时NCT06757634

• Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

  II 期招募中South KoreaNCT06837792

• SNF Platform Study of HR+/ HER2-advanced Breast Cancer

  II 期招募中中国NCT05594095

• Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

  II 期招募中South KoreaNCT05536128

• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

  II 期招募中中国NCT05759546

• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

  I 期 / II 期招募中中国NCT07708194

• Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

  II 期招募中美国NCT05472792

• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

  II 期招募中美国NCT05524584

• SNV4818 in Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国澳大利亚加拿大NCT06736704

• Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

  I 期 / II 期招募中美国NCT07558733

• Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

  II 期招募中美国NCT05113368

• Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  II 期招募中中国NCT07180160

• Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

  II 期招募中美国NCT07227233

• A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

  不适用招募中中国NCT06856200

• Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

  IV 期招募中德国瑞士NCT05362760

• Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

  I 期 / II 期招募中中国NCT06950086

• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

  II 期招募中中国NCT06341894

• Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

  I 期招募中美国NCT06663072

• A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors

  I 期 / II 期招募中中国NCT06555068

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。